Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.

Huo, Xingfa; Shen, Guoshuang; Liu, Zhen; Liang, Yuhua; Li, Jinming; Zhao, Fuxing; Ren, Dengfeng; Zhao, Jiuda

Huo, Xingfa; Shen, Guoshuang; Liu, Zhen; Liang, Yuhua; Li, Jinming; Zhao, Fuxing; Ren, Dengfeng; Zhao, Jiuda.

Afiliación

Huo X; Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China. Electronic address: xingfahuo@126.com.
Shen G; Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China. Electronic address: guoshuangshen@126.com.
Liu Z; Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China. Electronic address: qhdxlz@163.com.
Liang Y; Graduate School of Qinghai University & Qinghai Provincial People's Hospital, Xining 810000, China. Electronic address: lyh970128@126.com.
Li J; Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China. Electronic address: jinmingli0212@163.com.
Zhao F; Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China. Electronic address: 18797349621@163.com.
Ren D; Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China. Electronic address: dengfeng1104@126.com.
Zhao J; Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China. Electronic address: jiudazhao@126.com.

Crit Rev Oncol Hematol ; 168: 103530, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34801695

Asunto(s)

Neoplasias de la Mama Triple Negativas; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Antígeno B7-H1; Humanos; Inmunoterapia; Supervivencia sin Progresión; Ensayos Clínicos Controlados Aleatorios como Asunto; Neoplasias de la Mama Triple Negativas/tratamiento farmacológico

Palabras clave

Atezolizumab; Durvalumab; Immune-checkpoint inhibitor; Immunotherapy; Metastatic triple-negative breast cancer; Pembrolizumab; Survival

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Crit Rev Oncol Hematol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google